荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09995 荣昌生物

未开盘 06-08 16:09:02

68.700

-1.800

-2.55%

最高70.500	最低67.400	成交量235.88万
今开69.450	昨收70.500	日振幅4.40%
总市值387.20亿	流通市值143.30亿	总股本5.64亿
成交额1.62亿	换手率1.13%	流通股本2.09亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09995","market":"HK","secType":"STK","nameCN":"荣昌生物","latestPrice":68.7,"timestamp":1780906142009,"preClose":70.5,"halted":0,"volume":2358838,"delay":0,"changeRate":-0.025531914893616982,"floatShares":208581239,"shares":563608243,"eps":1.4899677919879633,"marketStatus":"未开盘","change":-1.8,"latestTime":"06-08 16:09:02","open":69.45,"high":70.5,"low":67.4,"amount":162435273,"amplitude":0.043972,"askPrice":68.7,"askSize":500,"bidPrice":68.6,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":2.6962618865745096,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780968600000},"marketStatusCode":0,"adr":0,"listingDate":1604851200000,"exchange":"SEHK","adjPreClose":70.5,"openAndCloseTimeList":[[1780882200000,1780891200000],[1780894800000,1780905600000]],"volumeRatio":0.49954421666489274,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"荣昌生物","latestPrice":97.47,"timestamp":1780902000000,"preClose":101.5,"halted":0,"volume":7600200,"delay":0,"premium":"-38.98"}},"requestUrl":"/m/hq/s/09995","defaultTab":"news","newsList":[{"id":"2641485599","title":"荣昌生物：注射用泰它西普治疗干燥综合征上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2641485599","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641485599?lang=zh_cn&edition=full","pubTime":"2026-06-08 18:22","pubTimestamp":1780914120,"startTime":"0","endTime":"0","summary":"6月8日，荣昌生物（688331/09995）发布公告，公司收到国家药品监督管理局核准签发的药品注册证书，注射用泰它西普治疗干燥综合征（干燥病）的新适应症上市申请获批。泰它西普是公司自主研发的全球首个BLyS/APRIL双靶点创新药，通过同时抑制BLyS和APRIL与B细胞表面受体结合，阻断B细胞异常分化和成熟，更好地控制疾病活动。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606083763744625.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IPOS","BK1161","LU2328871848.SGD","LU1064130708.USD","LU1064131003.USD","688331","BK1574","LU1969619763.USD","LU2148510915.USD","BK1583","LU2488822045.USD","09995","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152558436","title":"荣昌生物发布2026年5月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1152558436","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152558436?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:43","pubTimestamp":1780562598,"startTime":"0","endTime":"0","summary":"荣昌生物制药（烟台）股份有限公司于2026年6月4日披露截至2026年5月31日的股份变动月报表。公告显示，公司本月未发生新增发行、购买、注销或转让库存股份等情况，股本结构保持稳定。根据月报，荣昌生物制药（烟台）股份有限公司的注册股本合计为人民币564,477,483元，本月未发生变动。两类股份的已发行及未发行股份数目均无新增或减少情形，总股本保持在564,477,483股。本次公告由公司董事王威东签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174198904","title":"荣昌生物4月股份变动月报表：股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1174198904","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174198904?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:36","pubTimestamp":1780562211,"startTime":"0","endTime":"0","summary":"2026年6月4日，荣昌生物制药（烟台）股份有限公司披露截至2026年4月30日的股份变动月报表。报告显示，报告期内公司无新增发行、购回或注销股份活动，总股本保持稳定。根据公告，截至2026年4月末，荣昌生物制药（烟台）股份有限公司法定/注册股本合计为人民币564,477,483元，普通股分为H股与A股两类，面值均为每股人民币1元。公司表示，截至2026年4月30日，其H股公众持股量符合香港联交所《上市规则》所规定的最低要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145352251","title":"异动解读 | 中美监管壁垒抬升压制估值，荣昌生物盘中大跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=1145352251","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145352251?lang=zh_cn&edition=full","pubTime":"2026-06-03 13:08","pubTimestamp":1780463339,"startTime":"0","endTime":"0","summary":"荣昌生物今日盘中股价大跌5.02%，引发市场关注。消息面上，股价下跌主要受中美生物科技领域监管环境变化影响。美国议员近期提议将生物技术纳入COINS法案管制范畴，旨在限制美资流入中国创新药企。同时，市场传闻国内拟对创新药海外授权（BD）交易增设前置审批。中美双向监管壁垒的同步抬升，直接冲击了创新药板块的出海逻辑与估值核心。此外，东方证券此前减持了荣昌生物16万股，ETF资金也呈现持续净流出态势，板块整体承压，同行业个股普遍下跌。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145134300","title":"异动解读｜荣昌生物盘中下跌5.02%，中美生物科技双向监管壁垒抬升持续压制创新药出海估值","url":"https://stock-news.laohu8.com/highlight/detail?id=1145134300","media":"行情直击","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145134300?lang=zh_cn&edition=full","pubTime":"2026-06-03 13:08","pubTimestamp":1780463280,"startTime":"0","endTime":"0","summary":"6月3日，荣昌生物盘中下跌5.02%，报72.85港元/股，成交额1.57亿港元，延续近期弱势走势。消息面上，美国议员近期提议将生物技术纳入COINS法案管制范畴，限制美资流入中国创新药企；同时市场传闻国内拟对创新药海外BD交易增设前置审批，中美双向监管壁垒同步抬升，直接冲击板块估值核心逻辑。此外，东方证券此前减持荣昌生物16万股，ETF资金持续净流出，板块整体承压。同行业个股普跌，康方生物跌3.1%、三生制药跌4.03%、信达生物跌2.92%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640932958","title":"荣昌生物(09995)拟以3亿元的闲置自有资金向浦发银行烟台分行购买理财产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2640932958","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640932958?lang=zh_cn&edition=full","pubTime":"2026-06-01 16:46","pubTimestamp":1780303573,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物(09995)发布公告，于2026年6月1日，本公司进一步与浦发银行烟台分行订立浦发银行理财产品8号协议，据此本公司同意以人民币3亿元的闲置自有资金向浦发银行烟台分行购买理财产品。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448495.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0086","SGXZ81163826.USD","BK0239","LU0469268626.HKD","BK0015","LU1808992512.USD","BK0278","LU2488822045.USD","BK0028","BK0187","BK1574","BK0183","BK0188","BK1583","LU1064131003.USD","LU1969619763.USD","LU2328871848.SGD","BK0012","BK1161","SGXZ49509284.SGD","LU1979443071.USD","BK0201","09995","LU1934453819.USD","688331","LU1064130708.USD","600000","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139932624","title":"异动解读 | 监管施压与机构减持双重打击，荣昌生物盘中大跌5.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=1139932624","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139932624?lang=zh_cn&edition=full","pubTime":"2026-06-01 11:37","pubTimestamp":1780285036,"startTime":"0","endTime":"0","summary":"荣昌生物今日盘中股价出现大幅下跌，跌幅达5.38%，市场关注度迅速升温。消息面上，多重因素共同导致了此次股价承压。同时，市场传闻国内监管机构拟对创新药企的海外业务发展交易增设前置审批，中美双向监管壁垒的抬升，直接冲击了板块的估值逻辑。此外，具体到公司层面，东方证券近期减持了荣昌生物16万股，同时相关ETF资金也出现连续多日的净流出。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112935446","title":"异动解读｜荣昌生物盘中下跌5.08%，中美生物科技博弈升级叠加创新药板块持续承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1112935446","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112935446?lang=zh_cn&edition=full","pubTime":"2026-06-01 11:10","pubTimestamp":1780283414,"startTime":"0","endTime":"0","summary":"6月1日，荣昌生物盘中下跌5.08%，报78.45港元/股，成交额3.05亿港元。消息面上，美国议员近期提议将生物技术纳入COINS法案管制范畴，限制美国资本流入中国创新药企，叠加市场传闻国内拟对创新药海外BD交易增设前置审批，双向监管壁垒抬升令板块估值逻辑承压。此外，东方证券近期减持荣昌生物16万股，ETF资金连续多日净流出，行业整体面临资金转向AI等赛道的风格切换阵痛，创新药出海预期受挫成为压制估值的核心因素。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639628589","title":"荣昌生物涨6.50%，东海证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2639628589","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639628589?lang=zh_cn&edition=full","pubTime":"2026-05-29 16:38","pubTimestamp":1780043890,"startTime":"0","endTime":"0","summary":"今日荣昌生物涨6.50%，收盘报116.03元。2026年4月3日，东海证券研究员杜永宏,付婷发布了对荣昌生物的研报《公司简评报告：商业化+BD驱动高增长，创新研发快速推进》，该研报对荣昌生物给出“买入”评级。公司经营效率不断提升，国际化进程加速，维持“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为23.03%。荣昌生物个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900030222.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688331","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131429732","title":"港股异动｜创新药概念股拉升，信达生物涨近13%，石药集团、荣昌生物涨7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1131429732","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131429732?lang=zh_cn&edition=full","pubTime":"2026-05-29 13:44","pubTimestamp":1780033481,"startTime":"0","endTime":"0","summary":"诺诚健华涨超5%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"14627b4c07acfccfc4c1fb81226a69da","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","09995","09969","01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106293009","title":"异动解读｜荣昌生物盘中上涨5.13%，泰它西普新适应症临床推进叠加板块共振","url":"https://stock-news.laohu8.com/highlight/detail?id=1106293009","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106293009?lang=zh_cn&edition=full","pubTime":"2026-05-29 13:32","pubTimestamp":1780032729,"startTime":"0","endTime":"0","summary":"5月29日，荣昌生物盘中上涨5.13%，报83.0港元/股，成交额2.42亿港元。此前泰它西普治疗IgA肾病的Ⅲ期临床结果已登上《新英格兰医学杂志》，临床管线持续兑现。荣昌生物是一家专注于抗体药物偶联物、抗体融合蛋白、单抗及双抗等治疗性抗体药物领域的生物医药公司，主要产品包括泰它西普、维迪西妥单抗等，应用于自身免疫疾病、肿瘤及眼科疾病领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638197575","title":"东方证券减持荣昌生物(09995)16万股 每股均价约84.83港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2638197575","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638197575?lang=zh_cn&edition=full","pubTime":"2026-05-26 19:30","pubTimestamp":1779795004,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，5月19日，东方证券减持荣昌生物(09995)16万股，每股均价84.8306港元，总金额约为1357.29万港元。减持后最新持股数目为1037.45万股，最新持股比例为4.97%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446169.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1574","EWH","BK0276","BK1161","LU1969619763.USD","BK1564","BK0239","BK0183","LU1064131003.USD","LU2328871848.SGD","BK0028","600958","09995","LU1064130708.USD","LU2488822045.USD","LU2148510915.USD","688331","03958","BK1147","BK0012","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638926345","title":"荣昌生物(09995)进一步购买6000万元的华泰证券理财产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2638926345","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638926345?lang=zh_cn&edition=full","pubTime":"2026-05-26 16:36","pubTimestamp":1779784596,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物(09995)发布公告，于2026年5月26日，本公司进一步与华泰证券订立华泰证券理财产品9号协议，据此本公司同意以人民币6000万元的闲置自有资金向华泰证券购买理财产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445974.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0188","LU0164865239.USD","LU1969619763.USD","688331","601688","LU1580142542.USD","BK0028","LU0531971595.HKD","LU1064130708.USD","BK0012","LU2148510915.USD","LU2328871848.SGD","BK1161","LU1934453819.USD","LU0039217434.USD","BK1583","LU1781817850.SGD","BK0276","LU0871576103.HKD","LU1808992512.USD","BK0183","LU1328615791.USD","LU2488822045.USD","09995","BK1574","LU1979443071.USD","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637086893","title":"荣昌生物遭汇添富基金减持16万股 每股作价约84.83港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2637086893","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637086893?lang=zh_cn&edition=full","pubTime":"2026-05-24 16:30","pubTimestamp":1779611400,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　香港联交所最新资料显示，5月19日，汇添富基金减持荣昌生物（09995）16万股，每股作价84.8306港元，总金额约为1357.29万港元。减持后最新持股数目为1037.45万股，最新持股比例为4.97%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-05-24/doc-inhyytnn4398818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2328871848.SGD","LU1969619763.USD","EWH","BK1161","LU2148510915.USD","LU2488822045.USD","688331","LU1064131003.USD","09995","LU1064130708.USD","BK0239","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637378691","title":"每周股票复盘：荣昌生物（688331）变更募投项目并调整注册资本","url":"https://stock-news.laohu8.com/highlight/detail?id=2637378691","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637378691?lang=zh_cn&edition=full","pubTime":"2026-05-24 01:17","pubTimestamp":1779556631,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，荣昌生物报收于116.7元，较上周的114.66元上涨1.78%。公司公告汇总荣昌生物第二届董事会第三十八次会议审议通过多项议案，包括部分募投项目子项目变更及金额调整、董事会换届选举非独立董事和独立董事候选人、变更注册资本并修订公司章程、修订及制定部分内部管理制度，并提请召开2025年年度股东会。荣昌生物拟对A股首次公开发行募集资金投资项目中的“抗肿瘤抗体新药研发项目”部分临床试验子项目进行调整。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400000123.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1583","BK0239","LU1064130708.USD","LU2488822045.USD","09995","LU1064131003.USD","LU1969619763.USD","LU2328871848.SGD","688331","BK1574","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637831217","title":"汇添富基金减持荣昌生物(09995)16万股 每股作价约84.83港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2637831217","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637831217?lang=zh_cn&edition=full","pubTime":"2026-05-22 20:49","pubTimestamp":1779454173,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，5月19日，汇添富基金减持荣昌生物(09995)16万股，每股作价84.8306港元，总金额约为1357.29万港元。减持后最新持股数目为1037.45万股，最新持股比例为4.97%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445275.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064131003.USD","EWH","BK1161","LU2328871848.SGD","LU2488822045.USD","LU2148510915.USD","LU1969619763.USD","688331","09995","BK0239","LU1064130708.USD","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151063469","title":"异动解读｜荣昌生物盘中上涨3.55%，生物科技板块集体反弹叠加基本面利好共振","url":"https://stock-news.laohu8.com/highlight/detail?id=1151063469","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151063469?lang=zh_cn&edition=full","pubTime":"2026-05-21 09:51","pubTimestamp":1779328314,"startTime":"0","endTime":"0","summary":"5月21日，荣昌生物盘中上涨3.55%，报88.25港元，成交额1.09亿港元。消息面上，生物科技板块整体走强，康方生物涨6.96%、科伦博泰生物涨3.52%、信达生物涨3.09%，板块联动效应显著。基本面方面，公司董事长近日表示泰它西普凭借FDA孤儿药资格认定，几乎不受美国集采降价政策影响，海外临床与FDA沟通顺利；一季度营收6.56亿元同比增长24.76%，归母净利润3.28亿元成功扭亏，9家机构给出买入评级，目标均价150.8元，多重利好共振推动股价修复。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636881660","title":"荣昌生物董事长王威东：国内销售、海外授权双向赋能丨21健谈","url":"https://stock-news.laohu8.com/highlight/detail?id=2636881660","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636881660?lang=zh_cn&edition=full","pubTime":"2026-05-20 14:46","pubTimestamp":1779259586,"startTime":"0","endTime":"0","summary":"2026年一季度创新药企业绩成绩单出炉，荣昌生物（688331.SH/9995.HK）经营成效显著。数据显示，报告期内荣昌生物营收6.56亿元，同比增长24.76%，归母净利润3.28亿元，较上年同期成功扭亏为盈。对于创业十八年的老牌企业荣昌生物而言，盈利意味着战略姿态的主动化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605203743371973.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605203743371973.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2488822045.USD","BK1574","LU1064130708.USD","LU2148510915.USD","LU2328871848.SGD","BK1583","09995","688331","BK0239","BK1161","LU1064131003.USD","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168242057","title":"荣昌生物再斥0.35亿元购买华泰证券理财，12个月内累计投向4.88亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1168242057","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168242057?lang=zh_cn&edition=full","pubTime":"2026-05-19 19:21","pubTimestamp":1779189711,"startTime":"0","endTime":"0","summary":"荣昌生物5月19日公告，再度动用闲置自有资金0.35亿元，与华泰证券签订两份新理财协议。至此，公司在12个月内累计向同一机构认购理财金额达4.88亿元，占此前董事会批准的25亿元现金管理额度的19.52%。\\n\\n此前5月14日，荣昌生物已通过华泰证券认购四款理财产品，合计4.53亿元。本次新增0.35亿元后，公司与华泰证券的六笔理财协议因在12个月内与同一金融机构办理且性质相似，需合并计算。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636853600","title":"荣昌生物(09995)进一步购买3500万元的华泰证券理财产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2636853600","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636853600?lang=zh_cn&edition=full","pubTime":"2026-05-19 19:20","pubTimestamp":1779189643,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物(09995)公布，于2026年5月19日，公司进一步与华泰证券订立(1)华泰证券理财产品5号协议，据此公司同意以人民币1500万元的闲置自有资金向华泰证券购买理财产品;及(2)华泰证券理财产品6号协议，据此公司同意以人民币2000万元的闲置自有资金向华泰证券购买理财产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443564.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601688","LU0039217434.USD","09995","LU1934453819.USD","BK0276","LU1328615791.USD","688331","LU0871576103.HKD","LU1064130708.USD","BK0012","BK0188","BK1161","LU2328871848.SGD","LU2148510915.USD","BK0183","LU1808992512.USD","LU1979443071.USD","BK0239","BK0028","LU2488822045.USD","LU0164865239.USD","LU1580142542.USD","LU0531971595.HKD","LU1064131003.USD","BK1583","LU1781817850.SGD","BK1574","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.1237},{"period":"1month","weight":-0.2968},{"period":"3month","weight":-0.2324},{"period":"6month","weight":-0.1101},{"period":"1year","weight":0.4935},{"period":"ytd","weight":-0.0458}],"compareEarnings":[{"period":"1week","weight":-0.0292},{"period":"1month","weight":-0.0658},{"period":"3month","weight":-0.0502},{"period":"6month","weight":-0.0346},{"period":"1year","weight":0.0363},{"period":"ytd","weight":-0.038}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"荣昌生物制药（烟台）股份有限公司是一家主要从事生物医药研究、生物医药服务及生物医药生产和销售的中国公司。该公司专注于抗体药物偶联物（ADC）、抗体融合蛋白、单抗及双抗等治疗性抗体药物领域。该公司的主要产品包括泰它西普、维迪西妥单抗、RC28-E等。该公司的产品主要应用于自身免疫疾病、肿瘤疾病、眼科疾病等重大疾病领域。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.110172},{"month":2,"riseRate":0.666667,"avgChangeRate":0.167223},{"month":3,"riseRate":0.5,"avgChangeRate":0.012545},{"month":4,"riseRate":0.833333,"avgChangeRate":0.095268},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.049233},{"month":6,"riseRate":0.666667,"avgChangeRate":0.078334},{"month":7,"riseRate":0.6,"avgChangeRate":-0.032319},{"month":8,"riseRate":0.4,"avgChangeRate":0.068611},{"month":9,"riseRate":0.6,"avgChangeRate":0.099222},{"month":10,"riseRate":0.4,"avgChangeRate":0.027845},{"month":11,"riseRate":1,"avgChangeRate":0.038747},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.053467}],"exchange":"SEHK","name":"荣昌生物","nameEN":"REMEGEN"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荣昌生物(09995)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荣昌生物,09995,荣昌生物股票,荣昌生物股票老虎,荣昌生物股票老虎国际,荣昌生物行情,荣昌生物股票行情,荣昌生物股价,荣昌生物股市,荣昌生物股票价格,荣昌生物股票交易,荣昌生物股票购买,荣昌生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荣昌生物(09995)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}